Inotrem raises €39M series B for septic shock therapy, diagnostic

A €39 million ($43 million) series B round raised by Inotrem will allow the French biotech to get its lead program for septic shock through Phase IIb testing.

Morningside Ventures

Read the full 294 word article

How to gain access

Continue reading with a
two-week free trial.